The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2018 | Mogamulizumab: an exciting antibody for autoimmunity
Martine Bagot, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the exciting new approval of the antibody mogumulizumab for cutaneous T-cell lymphoma. Speaking at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, she presents two case studies of patients who developed autoimmunity, where they entered complete remission for a significant period of time after receiving injections of this antibody. Prof. Bagot is excited about the therapy and accounts the antibodies successful response to its potential mechanism of regulatory T-cell depletion.
